Steroid-dependent Crohn’s disease

William J Sandborn MD

Placebo controlled trials have demonstrated that a tapering course of corticosteroids is an effective therapy for active Crohn’s disease. A population-based study of 109 patients with Crohn’s disease undergoing their first course of corticosteroids showed that, at the end of one year, 44% of patients were steroid responsive, 36% were steroid dependent and 20% were steroid refractory. Side effects occur frequently during a four-month tapering course of corticosteroids, including moon face, acne, infection, ecchymoses, hypertension, hirsutism, petechial bleeding and striae. More serious side effects occur with long term use, including hypertension, diabetes, infection, osteonecrosis, osteoporosis, myopathy, cataracts, glaucoma and psychosis. Low dose corticosteroids, alternate-day corticosteroids and mesalamine (5-aminosalicylate) are not effective steroid-sparing agents in patients with Crohn’s disease. Controlled ileal release budesonide, 6 mg/day, is an effective steroid-sparing agent, but it does result in some decrease in adrenal function. Azathioprine, 6-mercaptopurine and methotrexate are all effective steroid-sparing agents, as is the humanized, anti-tumour necrosis factor monoclonal antibody, CDP571. A preliminary, uncontrolled study has suggested that the mouse/human chimeric monoclonal antibody infliximab may also be steroid sparing. Surgical resection is an effective strategy to reduce steroid use in the short to intermediate term, but postoperative reoccurrence of Crohn’s disease occurs frequently. Given the morbidity associated with prolonged corticosteroid use, medical and surgical treatment strategies to reduce steroid use should be employed routinely.

Key Words: Corticosteroids; Crohn’s disease; Infliximab; Steroid-dependent patients; Steroid-sparing medications

Corticosteroids are effective for inducing remission in patients with Crohn’s disease, but they are not safe at high doses for maintaining remission and they are not effective at low doses for maintaining remission. Because of the lack of effective alternative medical therapies and the morbidity associated with surgery, many patients, in the past, have been maintained for prolonged periods of time on corticosteroids at moderate to high doses. This treatment approach is no longer appropriate given the availability of a variety of other medications with steroid-sparing properties.

Maladie de Crohn et dépendance aux stéroïdes

RÉSUMÉ : Des essais contrôlés contre placebo montrent que la corticothérapie dégressive constitue un traitement efficace de la maladie de Crohn en évolution. Cent neuf patients atteints de la maladie de Crohn et soumis pour la première fois à un traitement aux corticostéroïdes ont participé à une étude fondée sur la population : au bout d’un an, 44 % d’entre eux étaient sensibles aux stéroïdes, 36 % y étaient dépendants et 20 % y étaient réfractaires. La corticothérapie dégressive d’une durée de quatre mois s’est accompagnée, dans bien des cas, d’effets indésirables comme le faciès lunaire, l’acné, les infections, les ecchymoses, l’hypertension, l’hirsutisme, les pétèches et les vergetures. Des effets indésirables plus sérieux ont été observés au cours de traitements prolongés, notamment l’hypertension, le diabète, les infections, l’ostéonécrose, l’ostéoporose, les myopathies, les cataractes, le glaucome et la psychose. Les corticostéroïdes à faible dose, pris aux deux jours, et la mesalamine (5-aminosalicylate) ne sont pas des épargneurs de stéroïdes efficaces chez les patients atteints de la maladie de Crohn. Le budesonide à libération lente dans l’iléon, administré à raison de 6 mg/jour, s’avère un épargneur de stéroïdes efficace, mais il entraîne une diminution du fonctionnement surrénalien. Azathioprine, la 6-mercaptopurine et le méthotrexate sont tous des épargneurs de stéroïdes efficaces, de même que l’anticorps monoclonal humanisé anti-facteur de nécrose des tumeurs, le CDP571. Selon une étude préliminaire non contrôlée, l’infliximab, un anticorps monoclonal chimérique souris-humain, aurait des propriétés d’épargne des stéroïdes. La résection chirurgicale offre une stratégie efficace pour diminuer l’utilisation des stéroïdes à court et à moyen terme, mais les récurrences de la maladie de Crohn ne sont pas rares après les opérations. Compte tenu de la morbidité associée à l’usage prolongé des corticostéroïdes, il serait approprié d’avoir recours autant aux stratégies de traitement médical qu’aux stratégies de traitement chirurgical pour diminuer l’utilisation des stéroïdes.
This article reviews the efficacy and toxicity associated with conventional corticosteroid therapy; defines steroid dependence; describes the natural history of steroid therapy in Crohn’s disease; outlines ineffective and effective steroid-sparing strategies; and gives the natural history of the postoperative reoccurrence of Crohn’s disease.

**EFFICACY AND TOXICITY OF CONVENTIONAL CORTICOSTEROIDS**

In the National Cooperative Crohn’s Disease Study (NCCDS), prednisone at a dosage of 0.25 to 0.75 mg/kg/day induced remission in 78% of patients with active Crohn’s disease compared with only 49% of placebo-treated patients (1). Similarly, in the European Cooperative Crohn’s Disease Study (ECCDS), 6-methylprednisolone at a dose of 48 mg/day induced remission in 83% of patients with active Crohn’s disease compared with only 38% of placebo-treated patients (2). These two studies clearly demonstrated that a tapering course of conventional corticosteroids, beginning at a high dose, is an effective therapy for active Crohn’s disease. Unfortunately, corticosteroid toxicity occurred frequently over 17 weeks of therapy. Toxicities observed included a moon face in 47% of patients, acne in 30%, infection in 27%, ecchymoses in 17%, hypertension in 15%, hirsutism in 7%, petechial bleeding in 6% and striae in 6% (3). Thus, high dose corticosteroids are effective, but the side effects preclude prolonged treatment.

Low dose corticosteroids cause fewer side effects, and thus maintenance studies with low dose corticosteroids in patients with Crohn’s disease in remission were undertaken. In the NCCDS, maintenance therapy with prednisone at a dosage of 0.25 mg/kg/day (20 mg/day) was not effective compared with placebo for maintaining remission (1). Similarly, in the ECCDS, 6-methylprednisolone at a dose of 8 mg/day was not effective compared with placebo for maintaining remission (2). The two studies showed that low dose, conventional corticosteroids are not effective in maintaining remission in patients with Crohn’s disease. Nevertheless, clinical experience has demonstrated that some patients have an improved clinical course while taking low to intermediate doses of corticosteroids (prednisone dose equivalent of 15 to 30 mg/day). Such patients have been deemed to be steroid dependent.

**NATURAL HISTORY OF STEROID THERAPY IN PATIENTS WITH CROHN’S DISEASE**

Munkholm and colleagues (4) reported on the clinical course of a population-based cohort of 109 patients with Crohn’s disease who received an initial course of corticosteroid therapy. They defined a steroid-responsive state as a complete or partial clinical response to 40 to 60 mg/day of prednisone and no regression of clinical symptoms 30 days after prednisone treatment was completed. A steroid-dependent state was defined as a partial or complete clinical response to treatment with prednisone 40 to 60 mg/day and a relapse within 30 days after prednisone treatment was completed or relapse with a dose reduction of prednisone resulting in the use of prednisone at doses greater than or equal to 15 mg/day for at least six...
months. A steroid-refractory state was defined as no response to prednisone at doses of 40 to 60 mg/day. Using these definitions, the outcomes at one month and one year are shown in Figures 1 and 2. Overall, at one year, 44% of patients were steroid responsive, 36% were steroid dependent, and 20% were steroid refractory.

**TOXICITY ASSOCIATED WITH PROLONGED STEROID THERAPY**

Prolonged corticosteroid therapy at low to intermediate doses (doses frequently used in steroid-dependent patients) is associated with the potential for multiple serious side effects (5). Hypertension occurs in up to 20% of patients (6). New-onset diabetes mellitus, requiring initiation of hypoglycemic therapy, occurs at a frequency of 2.33 times greater than in the general population (7). Infection occurs at a frequency of 13% to 20% (8). Osteonecrosis occurs at a frequency of approximately 5% (9). The frequency of steroid-associated osteoporosis may be as high as 50% (10). Neurological side effects occur often and can include myopathy at a frequency of 7% and psychosis at a frequency of 3% to 5% (11). Ophthalmological side effects also occur, including cataracts at a frequency of 22% (dose-dependent) and glaucoma (frequency unclear, response genetically determined) (12,13).

**MEDICAL THERAPY STRATEGIES FOR STERIOD SPARING**

A variety of medical therapies have been evaluated as potential steroid-sparing agents for patients with steroid-dependent Crohn's disease. As discussed above, low dose corticosteroids are not effective for maintaining remission in patients in whom remission was induced with high dose corticosteroids (1,2). Other potential steroid-sparing strategies include alternate-day corticosteroids, controlled ileal release (CIR) budesonide, mesalamine (5- amino salicylate), 6-mercaptopurine and its prodrug azathioprine, methotrexate, the humanized, antitumour necrosis factor (TNF) monoclonal antibody CDP571 and infliximab.

**Alternate-day corticosteroids:** The rationale for alternate-day corticosteroid therapy is that this dosing schedule does not interfere with the normal ACTH-cortisol cycle and does not expose tissues to sustained concentrations of corticosteroids throughout the day (14-18). Alternate-day corticosteroid therapy appears to be as effective as daily steroid dosing in some but not all immunological diseases. Uncontrolled data have suggested that alternate-day corticosteroid therapy may be beneficial in patients with Crohn's disease and may be associated with fewer side effects than standard corticosteroid therapy (19). However, the evidence supporting this approach to therapy for Crohn's disease is minimal, and given the availability of nonsteroid alternatives, it is not recommended by most experts in the field.

**CIR budesonide:** CIR budesonide is effective in patients with active Crohn's disease at doses of 9 and 15 mg/day, but not 3 or 6 mg/day, compared with placebo (20). CIR budesonide is equivalent in efficacy to prednisolone 40 mg/day (21,22). In patients with a medically induced remission, maintenance therapy with CIR budesonide at doses of 3 or 6 mg/day was not effective compared with placebo (23,24). Thus, when considering the broad population of patients with Crohn's disease.

---

**Figure 2** Prolonged outcome (one year) after steroid treatment had finished in patients initially obtaining complete and partial remission (n=87). Reprinted with permission from reference 4.
disease who have achieved a medically induced remission, CIR budesonide at a dose of 6 mg/day is not effective as a maintenance therapy. Furthermore, while CIR budesonide 6 mg/day is reasonably well tolerated from a side effect standpoint, there is some decrease in adrenal function (23).

In contrast, in patients who are steroid-dependent at prednisone doses of 10 to 30 mg/day, CIR budesonide 6 mg/day is effective in maintaining remission and allowing a total withdrawal of prednisone in 68% of patients compared with only 35% of placebo-treated patients (25). The side effect profiles are similar in both groups. Based on these data, CIR budesonide 6 mg/day can be considered a steroid-sparing therapy. The safety of long term therapy with CIR budesonide at the 6 mg/day dose remains to be determined.

**Mesalamine:** Many clinicians assume that mesalamine has steroid-sparing properties. It is common in clinical practice to prescribe high dose mesalamine (4 to 4.8 g) in combination with a tapering course of corticosteroids. This approach was evaluated in a placebo controlled trial by Modigliani et al (26), who reported that the oral mesalamine formulation Pentasa (Ferring Inc) at a 4 g/day dose was not effective for steroid sparing in patients with active Crohn’s disease who required a tapering course of corticosteroids (26). This negative result is in accord with the evolving evidence that mesalamine is not effective for maintaining remission in patients with Crohn’s disease (27).

**Azathioprine and 6-mercaptopurine:** 6-mercaptopurine and its prodrug, azathioprine, are used in patients with Crohn’s disease for induction of remission, closure of fistulae, maintenance of remission and steroid sparing. The steroid-sparing properties of these medications are best illustrated by studies showing that 42% of patients treated with azathioprine 2.5 mg/kg/day were able to discontinue steroids compared with only 7% of placebo-treated patients (28), and that 85% of patients treated with 6-mercaptopurine 1.5 mg/kg/day were able to discontinue steroids compared with only 54% of placebo-treated patients (29). These medications are now the most widely used agents for steroid sparing in patients with Crohn’s disease.

**Methotrexate:** Methotrexate is also used for steroid sparing in patients with Crohn’s disease. Feagan et al (30) reported that 39% of patients treated with intramuscular methotrexate at a dose of 25 mg/week could successfully maintain remission and discontinue prednisone over 16 weeks compared with only 19% of placebo-treated patients. In a subsequent follow-up study, Feagan et al (31) demonstrated that maintenance therapy with intramuscular methotrexate 15 mg/week maintained remission for 40 weeks. Methotrexate is currently used for steroid sparing as a second-line immunosuppressive agent after azathioprine and 6-mercaptopurine have failed. However, the available efficacy data are robust, and the choice between azathioprine or 6-mercaptopurine, and methotrexate is now becoming one of patient and physician personal preference.

**Anti-TNF antibody therapy:** A recent study with the humanized, anti-TNF monoclonal antibody CDP571 showed a steroid-sparing effect, with 44% of CDP571-treated patients maintaining remission and discontinuing prednisone compared with only 22% of placebo-treated patients (32). The mouse/human chimeric monoclonal antibody to TNF, infliximab, is effective for patients with active Crohn’s disease, for closing Crohn’s disease fistulae and for maintaining remission in patients with Crohn’s disease (33-35). To date, there are no placebo controlled data regarding the steroid-sparing potential of infliximab in patients with Crohn’s disease. However, uncontrolled data from the Mayo Clinic, Rochester, Minnesota suggest that infliximab is steroid sparing. Of the first 100 consecutive patients treated with infliximab at the Mayo Clinic, 61 had inflammatory disease and 39 had fistulizing disease. Ninety-five patients were receiving azathioprine, 6-mercaptopurine or methotrexate. In addition, 44 of the patients were receiving concomitant corticosteroids. Corticosteroid tapering was attempted in 40 of 44 patients, and total steroid withdrawal was possible in 29 of 40 patients (73%) (36).

**SURGICAL THERAPY STRATEGIES FOR STEROID SPARING**

Surgery is an effective and durable intervention for patients with refractory Crohn’s disease or complications from Crohn’s disease. This is equally true for patients with steroid-dependent Crohn’s disease. Nevertheless, the recurrence rates of Crohn’s disease following surgical resection are high. McLeod et al (37) reported that the rate of endoscopic or radiographic reoccurrence was 77% three years following a surgical resection. Munkholm et al (38) reported that the frequency of one operation 15 years after the diagnosis of Crohn’s disease was 34%, the frequency of two operations was 14%, the frequency of three operations or more was 22%, and the frequency of not having an operation at 15 years was only 30%. For patients with a previous operation, the likelihood of a repeat surgery in patients with ileitis and an ileocolonic anastomosis is 44%, the likelihood of a repeat surgery in patients with ileocolitis and an ileocolonic anasto-
mosis is 53%, and the likelihood of a repeat surgery in patients with Crohn's colitis and a segmental resection is 45% (39). For patients with isolated Crohn's colitis who undergo proctocolectomy with ileostomy, the likelihood of a repeat surgery is only 6%, whereas, in patients with ileocolitis who undergo proctocolectomy with ileostomy, the likelihood of requiring a repeat operation is 29% (40).

CONCLUSIONS
The safety and efficacy of various treatment options for steroid-dependent Crohn's disease are outlined in Table 1. Low dose corticosteroids and alternate-day corticosteroids are not effective and, thus, are inappropriate. CIR budesonide is effective, but the safety of long term therapy at a 6 mg/day dose is not clear. Mesalamine is not effective and thus is not appropriate. Azathioprine, 6-mercaptopurine and methotrexate are effective and reasonably safe agents for the steroid-sparing indication, and can be recommended for widespread clinical practice. The humanized, anti-TNF monoclonal antibody CDP 571 is investigational at the present time. When it becomes available clinically, it could also be recommended as a steroid-sparing therapy. Uncontrolled evidence suggests that infliximab is steroid sparing; a controlled, clinical trial is needed to confirm this preliminary observation. Surgical resection is effective and durable for steroid-dependent Crohn's disease, but both short and long term postsurgical morbidity issues are important, and the rates of reoccurrence and reoperation after surgical resection are high. Given the morbidity associated with prolonged corticosteroid use, medical and surgical treatment strategies to accomplish steroid sparing should be employed routinely.

REFERENCES
1. Summers RW, Switz DN, Sessions JT, et al. National Cooperative Crohn's Disease Study: results of drug treatment. Gastroenterology 1979;77:847-69.
2. Malchow H, Ewe K, Brandes JW, et al. European Cooperative Crohn's Disease Study (ECCDS): results of drug treatment. Gastroenterology 1984;86:249-66.
3. Singleton JW, Law DH, Kelly ML, Melhjian HS, Stundervall RAL. National Cooperative Crohn's Disease Study: adverse reactions to study drugs. Gastroenterology 1979;77:870-82.
4. Munkholm P, Langholt E, Davidsen M, Binder V. Frequency of glucocorticoid resistance and dependency in Crohn's disease. Gut 1994;35:360-2.
5. Talar-Williams C, Sneller MC. Complications of corticosteroid therapy. Eur Arch Ophthalmol 1994;251:131-6.
6. Whitworth JA. Mechanisms of glucocorticoid-induced hypertension. Kidney Int 1987;31:1213-24.
7. Gurwitz JH, Bohn RL, Grynn RJ, Monane M, Mogun H, Avorn J. Glucocorticoids and the risk for initiation of hypoglycemic therapy. Arch Intern Med 1994;154:97-101.
8. Stuck AE, Minder CE, Frey FJ. Risk of infectious complications in patients taking glucocorticoids. Rev Infect Dis 1989;11:954-63.
9. Mankin HJ. Nontraumatic necrosis of bone (osteonecrosis). N Engl J Med 1992;326:1473-9.
10. Lukert B, Raisz LG. Glucocorticoid-induced osteoporosis. Rheum Dis Clin North Am 1994;20:29-50.
11. Lacomis D, Samuels MA. Adverse neurologic effects of glucocorticoids. J Gen Intern Med 1991;6:367-77.
12. Urban RC, Cotlier E. Corticosteroid-induced cataracts. Surv Ophthalmol 1986;31:102-10.
13. Urban RC, Dreyer EB. Corticosteroid-induced glaucoma. Int Ophthalmol Clin 1993;33:135-9.
14. Fauci AS. Alternate-day corticosteroid therapy. Am J Med 1978;64:279-31.
15. Ackerman GL, Nolan CM. Adrenocortical responsiveness after alternate-day corticosteroid therapy. N Engl J Med 1968;278:405-9.
16. Dale DC, Fauci AS, Wolff SM. Alternate-day prednisone. Leukocyte kinetics and susceptibility to infections. N Engl J Med 1974;291:1154-8.
17. MacGregor RR, Sheagren JN, Lipsitt MB, Wolff SM. Alternate-day prednisone therapy. Evaluation of delayed hypersensitivity reactions, control of disease and steroid side effects. N Engl J Med 1969;280:1427-31.
18. Harter JG, Reddy WJ, Thorn GW. Studies on an intermittent corticosteroid dosage regimen. N Engl J Med 1963;269:591-6.
19. Bello C, Goldstein F, Thornton JJ. Alternate-day prednisone treatment and treatment maintenance in Crohn's disease. Am J Gastroenterol 1991;86:460-6.
20. Greenberg GR, Feagan BG, Martin F, et al, and the Canadian Inflammatory Bowel Disease Study Group. Oral budesonide for active Crohn's disease. N Engl J Med 1994;331:836-41.
21. Rutgeerts P, Loffert R, Malchow H, et al. A comparison of budesonide with prednisolone for active Crohn's disease. N Engl J Med 1994;331:842-5.
22. Campieri M, Ferguson A, Doe W, Tersson T, Nilsson LG, and the Global Budesonide Study Group. Oral budesonide is as effective as oral prednisolone in active Crohn's disease. Gut 1997;41:209-14.
23. Greenberg G, Feagan B, Martin F, et al, and the Canadian inflammatory bowel disease study group. Oral budesonide as maintenance treatment for Crohn's disease: a placebo-controlled dose-ranging study. Gastroenterology 1996;110:45-51.
24. Loffert R, Rutgeerts P, Malchow H, et al. Budesonide prolongs time to relapse in ileal and ileocecal Crohn's disease. A placebo controlled one year study. Gut 1996;39:82-6.
25. Cortot A, Colombel JP, Rutgeerts P, et al, International Budesonide Study Group. Budesonide controlled ileal release (CIR) capsules in prednisolone-dependent patients with Crohn's disease. Gastroenterology 1999;116:A692-3.
26. Modigliani R, Colombel JP, Dupas JL, et al. Group d'Etudes Therapeutiques des Affections Inflammatoires Digestives. Mesalamine in Crohn's disease with steroid-induced remission: effect on steroid withdrawal and remission maintenance. Gastroenterology 1996;110:688-93.
27. Camma C, Giunta M, Rosselli M, Crotone M. Mesalamine in the maintenance treatment of Crohn's disease: a meta-analysis adjusted for confounding variables. Gastroenterology 1997;113:1465-73.
28. Candy S, Wright J, Gerber M, Adams G, Gerig M, Goodman R. A controlled double blind study of azathioprine in the management of Crohn's disease. Gut 1995;37:674-8.
29. Markowitz J, Grancher K, Mandal F, Baum F, and the 6MP Collaborative Group. 6-Mercaptopurine (6MP) + prednisone therapy for newly diagnosed pediatric Crohn's disease (CD): a prospective, multicenter, placebo-controlled clinical trial. Gastroenterology 1998;114:A1032.
30. Feagan BG, Rochon J, Fedorak RN, et al, for the North American Crohn's Disease Study Group Investigators. Methotrexate for the treatment of Crohn's disease. N Engl J Med 1995;332:292-7.
31. Feagan BG, Fedorak RN, Irvine EJ, et al. A comparison of methotrexate with placebo for the maintenance of remission of Crohn's disease. North American Crohn's Study Group Investigators. N Engl J Med 200;342;1627-32.
32. Feagan BG, Sandborn WJ, Baker JP, et al. A randomized, double-blind, placebo-controlled, multi-center trial of the engineered human antibody to TNF (CDP571) for steroid sparing and maintenance of remission in patients with steroid-dependent Crohn's disease. Gastroenterology 2001;120:1672-32.
33. Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999;340:1398-1405.
34. Targan SR, Hanauer SB, Van Deventer SJH, et al, for the Crohn's Disease Ca2 Study Group. A short-term study of chimeric monoclonal antibody Ca2 to tumor necrosis factor alpha antibody for Crohn's disease. N Engl J Med 1997;337:1029-35.
35. Rutgeerts P, D’Haens G, Targan S, et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn’s disease. Gastroenterology 1999;117:761-9.

36. Ricart E, Panaccione R, Loftus EV, Tremaine WJ, Sandborn WJ. Infliximab for Crohn’s disease in clinical practice at the Mayo Clinic: the first 100 patients. Gastroenterology 2000;118:A568. (Abst)

37. McLeod RS, Wolff BG, Steinhart AH, et al. Risk and significance of endoscopic/radiologic evidence of recurrent Crohn’s disease. Gastroenterology 1997;113:1823-7.

38. Munkholm P, Langholz E, Davidsen M, Binder V. Intestinal cancer risk and mortality in patients with Crohn’s disease. Gastroenterology 1993;105:1716-23.

39. Whelan G, Farmer RG, Fazio VW, Goormastic M. Recurrence after surgery in Crohn’s disease. Gastroenterology 1985;88:1826-33.

40. Ho I, Greenstein AJ, Bodian CA, Janowitz HD. Recurrence of Crohn’s disease in end ileostomies. Inflamm Bowel Dis 1995;1:173-8.
